Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by HARRIS, M. W
Right arrow Articles by BIRNBAUM, L. S
Right arrow Search for Related Content
PubMed
Right arrow Articles by HARRIS, M. W
Right arrow Articles by BIRNBAUM, L. S
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 Oxford University Press

research-article

Developmental Toxicity of Perfluorodecanoic Acid in C57BL/6N Mice

MARTHA W HARRIS and LINDA S BIRNBAUM

Systemic Toxicology Branch, National Institute of Environmental Health Sciences P.O. Box 12233, Research Triangle Park; North Carolina 27709

Received March 4, 1988; accepted August 8, 1988

Developmental Toxicity of Perfluorodecanoic Acid in C57BL/6N Mice. HARRIS, M. W., AND BIRNBAUM, L. S. (1989). Fundam Appl. Toxicol. 12, 442–448. Perfluorodecanoic acid (PFDA) is a representative of the perfluorinated carboxylic acids used as commercial wetting agents and flame retardants. Signs of PFDA toxicity have been reported to resemble those seen after exposure to TCDD. To determine if PFDA exhibits teratogenic effects similar to those of TCDD or is a developmental toxin, time-mated C57BL/6N mice were administered PFDA by gavage in corn oil (10 ml/kg) on gestation days (gd) 10–13 or gd 6–15 at levels of 0, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, or 32.0 mg/kg/day or 0, 0.03, 0.3, 1.0, 3.0, 6.4, or 12.8 mg/kg/day, respectively. Dams were killed on gd 18 and maternal and fetal toxicity was assessed. Fetuses were examined for external, visceral, or skeletal malformations. Maternal body weight gain (corrected for the weight of the gravid uterus) was significantly reduced as a result of PFDA treatment at 6.4 and 12.8 mg/kg/day (gd 6–15) and 16.0 and 32.0 mg/kg/day (gd 10–13). Fetal viability was decreased only in those groups showing extensive maternal body weight loss. Fetal body weights were significantly reduced at levels as low as 0.1 mg/kg/day (gd 6–15) and 0.5 mg/kg/day (gd 10–13). No hydronephrosis, cleft palate, or edema was observed nor were any other soft tissue or skeletal malformations detected. Thus, PFDA does not produce malformations in C57BL/6N mice, and the developmental toxicity observed (increased fetal mortality and decreased live fetal body weight) was seen only at doses that were maternally toxic.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.